Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing ...

The clinical trial is expected to enroll up to 40 patients in two stages: an initial open-label pilot (10 patients) followed by a randomized, double-blinded, sham-controlled trial (30 patients).

Currently, the MyoRegulator® device is under investigation as a non-invasive treatment for ALS in a second and larger clinical trial, the CALM ( C ontrolling A myotrophic L ateral Sclerosis M otor ...

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today ...

Public institutions across the world are reassessing how they identify and respond to narcotic impairment. Courts, ...

Harnessing a pervasive type of cellular messenger shows early experimental promise as a routine way of sampling and monitoring the body's response to prescription drug exposure. Experiments have ...

Nandita Vijayasimha, Bengaluru Friday, January 2, 2026, 08:00 Hrs [IST] ...

(RTTNews) - Intelligent Bio Solutions Inc. (INBS) announced Wednesday the rapid expansion of its Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark through its ...